News from the ASCO conference from June

[Guest guest]

I copied and pasted part of a report mentioning cll:

" Roche’s next generation of antibodies

Antibody-drug conjugates - featured at ASCO 2010 was phase Ib/II data on

the combination of T-DM1 and pertuzumab for advanced HER2-positive

breast cancer. T-DM1 is a ground-breaking ‘armed antibody’ combining the

therapeutic antibody, trastuzumab, with a cell-killing agent (DM1)

delivered directly to the tumour. Roche and Genentech have 50 new armed

antibodies in various stages of early research and development.

Glycoengineered antibodies - Roche and Genentech have also pioneered a

technology (glycoengineering) that enhances the ability of a monoclonal

antibody to induce an immune response against cancer cells.

Roche currently has several glycoengineered antibodies in development

including RG7159 (GA101) for the treatment of B-cell malignancies

(chronic lymphocytic leukemia and non-Hodgkin’s lymphoma) and RG7160

(GA201) that binds to Epidermal Growth Factor Receptor (EGFR) and has

shown promising early results in treating colorectal cancer. "

Ellen